10:00 ET -- Fulcrum Therapeutics is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Fulcrum Therapeutics has licensed the international rights to its proposed treatment for a rare, genetic muscular disorder to France's Sanofi in a deal potentially worth more than $1 billion to the clinical-stage biopharmaceutical company. Fulcrum said it will work with Sanofi on the development and commercialization of losmapimod. The agreement gives Sanofi exclusive commercialization rights for losmapimod outside the U.S., while Fulcrum, based in Cambridge, Mass., retains full U.S. commercialization rights. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)


(END) Dow Jones Newswires

05-13-24 1015ET